Comprehensive screening for antigens overexpressed on carcinomas via isolation of human mAbs that may be therapeutic

Division of Antibody Project, Institute for Comprehensive Medical Science, Fujita Health University, Toyoake, Aichi 470-1192, Japan.
Proceedings of the National Academy of Sciences (Impact Factor: 9.81). 06/2008; 105(20):7287-92. DOI: 10.1073/pnas.0712202105
Source: PubMed

ABSTRACT Although several murine mAbs that have been humanized became useful therapeutic agents against a few malignancies, therapeutic Abs are not yet available for the majority of the human cancers because of our lack of knowledge of which antigens (Ags) can become useful targets. In the present study we established a procedure for comprehensive identification of such Ags through the extensive isolation of human mAbs that may become therapeutic. Using the phage-display Ab library we isolated a large number of human mAbs that bind to the surface of tumor cells. They were individually screened by immunostaining, and clones that preferentially and strongly stained the malignant cells were chosen. The Ags recognized by those clones were isolated by immunoprecipitation and identified by MS. We isolated 2,114 mAbs with unique sequences and identified 21 distinct Ags highly expressed on several carcinomas. Of those 2,114 mAbs 356 bound specifically to one of the 21 Ags. After preparing complete IgG(1) Abs the in vitro assay for Ab-dependent cell-mediated cytotoxicity (ADCC) and the in vivo assay in cancer-bearing athymic mice were performed to examine antitumor activity. The mAbs converted to IgG(1) revealed effective ADCC as well as antitumor activity in vivo. Because half of the 21 Ags showed distinct tumor-specific expression pattern and the mAbs isolated showed various characteristics with strong affinity to the Ag, it is likely that some of the Ags detected will become useful targets for the corresponding carcinoma therapy and that several mAbs will become therapeutic agents.

Download full-text


Available from: Nobuhiro Hayashi, Aug 23, 2015
  • Source
    • "An alternative approach is to use phenotypic screening to identify disease relevant targets. In an elegant experiment, Kurosawa et al. (2008) used a phage-display antibody library to isolate human monoclonal antibodies (mAbs) that bind to the surface of tumour cells. Clones were individually screened by immunostaining and those that preferentially and strongly stained the malignant cells were chosen. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Developing a new drug from original idea to the launch of a finished product is a complex process which can take 12-15 years and cost in excess of $1 billion. The idea for a target can come from a variety of sources including academic and clinical research and from the commercial sector. It may take many years to build up a body of supporting evidence before selecting a target for a costly drug discovery programme. Once a target has been chosen, the pharmaceutical industry and more recently some academic centres have streamlined a number of early processes to identify molecules which possess suitable characteristics to make acceptable drugs. This review will look at key preclinical stages of the drug discovery process, from initial target identification and validation, through assay development, high throughput screening, hit identification, lead optimization and finally the selection of a candidate molecule for clinical development.
    British Journal of Pharmacology 11/2010; 162(6):1239-49. DOI:10.1111/j.1476-5381.2010.01127.x · 4.99 Impact Factor
  • dressNature Reviews Drug Discovery 06/2008; 7(7):561-561. DOI:10.1038/nrd2625 · 37.23 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Protein fragment complementation assay (PCA) is based on the interaction between two protein partners (e.g. target antigen and antibody), which are genetically fused to the two halves of a dissected marker protein. Binding of the two partners reassembles the marker protein and hence reconstitutes its activity. In this work we have developed the first application of beta-lactamase-based PCA for the isolation of single chain Fv fragments (scFvs) binding to the human receptor RON from a naïve library. Specific scFvs with the ability to immunoprecipitate could be isolated after a single round of PCA selection from an scFv repertoire previously pre-selected by phage display. Furthermore, the PCA was used to successfully map the epitopes recognized by the selected scFvs by screening them against a small library of random RON fragments.
    Protein Engineering Design and Selection 10/2008; 22(3):149-58. DOI:10.1093/protein/gzn053 · 2.32 Impact Factor
Show more